Drugs / TIL infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02926053 | Dec 2016 → Oct 2021 | renal cell carcinoma | Inge Marie Svane | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIL infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02926053 ↗ |
| Modality | Cell therapy | “Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL)” NCT02926053 ↗ |